After a trip to Beijing, the head of UNAIDS revealed what China is doing in the fight against AIDS in Africa. Winnie Byanyima said funding from China’s Global Development and South-South Cooperation Fund now supports prevention work in several countries, among them South Africa, Uganda, Lesotho and Zimbabwe, and she voiced gratitude for Beijing’s strong commitment to multilateralism. The sums involved are small. The moment they arrive in is not.
The United States built the global AIDS response. Its flagship program, PEPFAR, created in 2003, is credited with saving more than 26 million lives; as of the end of 2024 Washington was keeping more than 20 million people on antiretroviral treatment, some 560,000 of them children. Then the machinery was dismantled. In January 2025 the new administration paused all foreign assistance. A limited waiver kept life-saving treatment flowing for a time, but the rest was cut away piece by piece: the US terminated its agreement with UNAIDS in February 2025, USAID was dissolved, and PEPFAR’s full-scale programming is gone. UNAIDS now estimates that if those programs stay dead, the world will see 6.6 million additional new HIV infections and 4.2 million additional AIDS-related deaths between 2025 and 2029, and three million more children orphaned.
Hold those numbers next to the Chinese ones. The fund’s grants run to a few million dollars at a time. South Africa, which has about eight million people living with HIV, got a Chinese grant of $3.49 million last year to fund prevention work for over 50,000 young people, plus harm-reduction services for drug injectors. It is real money doing real work, and it is a rounding error against the scale of what the American programs spent and what their absence costs.
China’s play is not a copy of PEPFAR’s. Beijing is building its Health Silk Road on two things: grants to a small number of countries, and local medicine manufacturing, the idea that African states should make their own drugs rather than depend on a foreign payer’s pipeline. That is a genuinely different proposition, and it is landing at a moment when African governments are shopping for partners on their own terms. Zambia and Zimbabwe have declined the US bilateral health agreements that replaced PEPFAR, citing worries about data sovereignty and about who gets to see sensitive health information. In the old order, Washington set the terms. In the new one, the terms are negotiable, and China is offering a relationship with fewer demands attached.
Do not mistake the optics for the medicine. China is not replacing PEPFAR; it is positioning itself in the space PEPFAR left. The grants are cheap advertising for a patron’s role, a way of being present at the table where the next era of global health is being arranged, at a fraction of what the Americans paid. The manufacturing pitch is the more serious part: if African states can make their own antiretrovirals, the next crisis will not hinge on a donor’s budget line. But a factory does not pay for the pills. The treatment gap is a cash gap, and nothing in China’s current spending closes it.
The transition is happening whether anyone planned it. The United States is out, China is in at the margins, and the African states are choosing partners with their eyes open. In the meantime the arithmetic stands: millions of people on treatment, a funding hole measured in millions of deaths, and just a few million dollars arriving from a new direction. The only question that matters is whether anyone this time is paying the entire bill in full. So far, the answer is no one.